'De-risking the Valley of Death - How R&D companies can access the knowledge network to maximise success'
The Valley of Death phase in the development of an R&D company is identified as the phase from one to six years, where they are moving from lead generation through to phase 1 development. There are many hurdles and challenges to overcome during this time and many companies falter, hence the reference to the 'Valley of Death'.
Via a series of insightful keynotes and case studies this BioTuesday event will look at how R&D companies can bridge the valley by accessing and fully utilising the existing knowledge network.
Dr Chris Doherty | Managing Director, Alderley Park, Manchester Science Partnerships - Chris is leading the Alderley Park site regeneration project which included the site sale and stimulating new business ventures on the site. As Site Director of the Park, Chris is managing the further development of the bioscience campus.
Dr Nick Scott-Ram | Director of Commercial Development, Oxford Academic Health Science Network - Nick has over 25 years' experience in commercial and business development in the life sciences sector. He joined the Oxford AHSN in 2014. He has held senior roles in blue chip companies including PowderJect Pharmaceuticals and has worked extensively with SMEs and public bodies. He was awarded the MBE for services to life sciences in 2001.
Peter Dines | Investment Director, Head of Life Sciences, Fund Manager, Mercia EIS Funds - Peter joined the Group in 2015 as Head of Life Sciences & Biosciences, with over 20 years' experience in this sector. He is responsible for a number of the life science portfolio investments including Native Antigen, Aston Eyetech, Sarissa Diagnostics, Nuvision, and Intelligent Health. In 2016 he was also appointed the Fund Manager for Mercia Growth Funds with overall responsibility for SEIS/EIS Funds across the four Mercia sectors.
In addition to our keynote speakers, we will hear from several companies based at the BioHub in Alderley Park who have successfully utilized the knowledge and expertise network of ex-Astra Zeneca scientists after the company move from Alderley Park to Cambridge.
18:00 Welcome: John Harris, CEO, OBN and Ned Wakeman, Director, BioHub at Alderley Park
18:10 Keynote Presentations
18.40 Company Presentations
Professor Ruth Roberts | Company Director, ApconiX- an integrated toxicology and ion channel company at the forefront of innovative thinking in nonclinical toxicology and safety science
Steve McConchie | CEO, Aptus Clinical- who specialise in the provision of expert clinical research professionals
Paul Dickinson | Director of Product Performance, Seda Pharmaceutical Development Services - provide Pharmaceutical Development Services, Clinical Pharmacology Services and Consultancy for the Pharma Industry
Dave Cook | CSO, Blueberry Therapeutics - bring high value, innovative medicines to the market and have exclusive worldwide access to a nanodelivery platform, which significantly enhances delivery of drugs into cells and tissues
19.10 Panel discussion between presenters
19.30 Questions from the audience
20.00 Networking over drinks and canapés
Edmond Safra Lecture Theatre, Säid Business School, Park End St, Oxford OX1 1HP
OBN Member - first ticket complimentary, additional ticket £25+VAT
Non-members - £50+VAT
We look forward to welcoming you on the night.